/ 2 items

#BCAX↓

BCAX/ 03/25/2026 · 10:38 AM

BofA Calls Bicara Therapeutics a Buy – Sees Ficerafusp Alfa as Transformative

BofA starts coverage on Bicara Therapeutics with a Buy rating and $35 price target. Ficerafusp alfa shows strong potential in head and neck cancer with clear differentiation over standard care.

BCAX/ 10/13/2025 · 7:58 AM

FDA Grants Breakthrough Status to Promising Head and Neck Cancer Treatment

Bicara Therapeutics' ficerafusp alfa receives FDA Breakthrough Therapy Designation for HPV-negative head and neck cancer, showing impressive response rates and survival benefits.